The scrip was listed at Rs 96.90, at a premium of 90% compared with the initial public offer (IPO) price. The stock was currently frozen at its upper limit of 5% over its listing price.
The counter hit a high of Rs 101.74 and a low of Rs 96.90. About 4.20 lakh shares of the company changed hands at the counter.
Hamps Bio's IPO was subscribed 1003.33 times. The issue opened for bidding on 13 December 2024 and it closed on 17 December 2024. The price of the IPO was set at Rs 51 per share.
The IPO comprised fresh issue of 12,20,000 equity shares. The promoter and promoter group shareholding diluted to 71.99% from 100% pre-issue.
The company intends to utilize the net proceeds to purchase of plant and machinery for FMCG division, Enhancing the visibility and awareness of the brand and general corporate purpose.
Hamps Bio operates in two main areas: pharmaceuticals (including medicines and supplements) and freeze-dried/frozen foods. They sell over 180 products under the Hamps and FzyEzy brands through distributors, e-commerce platforms, and across eight states/territories for pharmaceuticals and a wider reach for food products (22 states/territories and 6 countries). As of 31 October 2024, the company had 78 employees.
The company recorded revenue from operations of Rs 4.26 crore and net profit of Rs 0.34 crore for the period as on 31 October 2024.